



PHARMA EQUITY GROUP

PROXY FORM

to the annual general meeting of Pharma Equity Group A/S Thursday, April 16, 2026, at 3:30 PM CEST
at Wihlborg's Canteens, Slotsmarken 15, DK-2970 Hørsholm

I, the Undersigned

Name of shareholder: _____

Address: _____

Zip code and city: _____

Custody account no. or VP reference: _____

hereby grant authority to attend and vote on my behalf at the annual general meeting of Pharma Equity Group A/S, Thursday, April 16, 2026 as set out below:

Please mark the appropriate box below or directly at www.pharmaequitygroup.dk or www.euronext.com/cph-agm.

A) Proxy is given to an identified third person: _____
Name and address of the proxy holder (please use capital letters)

or
B) Proxy is given to the Board of Directors (or order) to vote on my behalf in accordance with the Board of Director's recommendations as specified below.

or
C) Proxy with instructions to the Board of Directors.
Please mark the box "FOR", "AGAINST", or "ABSTAIN" below to indicate how you wish to cast your votes at the General Meeting.

Items on the agenda (the full agenda is included in the notice of the meeting)	FOR	AGAINST	ABSTAIN	Boards of Director's recommendations
1. The board of directors' report on the Company's activities in the past year.....	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	-
2. Presentation of the audited annual report for approval	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	For
3. Discharge to the executive board and the board of directors from liability.....	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	For
4. Adoption of appropriation of profit or loss as proposed by the board of directors.....	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	For
5. Presentation of the remuneration report 2025 for an advisory vote	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	For
6. Approval of remuneration to the board of directors for the current financial year	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	For
7. Election of the board of directors	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	-
Re-election of Christian Vinding Thomsen.....	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	For
Re-election of Omar S. Qandeel	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	For
Re-election of Charlotte Pahl.....	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	For
Election of Lars Gundorph.....	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	For
8. Election of auditors.....	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	-
Re-election of BDO Statsautoriseret Revisionsaktieselskab	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	For
9. Proposals from the board of directors or shareholders	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	-
A) Shareholder-proposed item regarding the basis for determining the exchange ratio of DKK 1.57 in connection with the contribution in kind of shares in Reponex Pharmaceuticals A/S	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
B) Proposal to increase and extend the authorization to issue new shares without pre-emption rights (article 4.1.B)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	For
C) Proposal to extend the authorization to issue warrants by one year (article 4.2).....	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	For
D) Proposal for authorization to issue convertible loans (new article 4.3.C).....	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	For
E) Proposal to approve an updated remuneration policy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	For
10. Authorization to the chair of the general meeting	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	For
11. Any other business.....	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	-

If the proxy form contains only date and signature, the votes will be deemed cast in accordance with the Board of Director's recommendations. If the form is only partly filled in, the votes in respect of agenda items for which no instructions are given will be deemed cast in accordance with the Board of Director's recommendations.

The proxy shall apply to all subjects discussed at the General Meeting. If new proposals are presented and put to the vote, including proposals for amendments or candidates not appearing on the agenda, the proxyholder shall vote on your behalf on accordance with his or her own convictions.

The proxy applies to the number of shares in the possession of the undersigned on the date of registration. The shareholding is calculated on the basis of the entry on the Company's register of shareholders and notifications on ownership that the Company has received, but has not yet entered in the register of shareholders.

_____|_____|_____|_____|**2**|**0**|**2**|**6**|
Date

Signature

The completed, dated and signed form must be received by Euronext Securities, Nicolai Eigtveds Gade 8, DK-1402 Copenhagen K, no later than **Friday, April 10, 2026 at 11:59 PM** by email to CPH-investor@euronext.com or by ordinary mail. If you hold a Danish electronic signature the proxy may also be granted electronically on the website: www.pharmaequitygroup.dk or www.euronext.com/cph-agm.